BR112016009954A2 - terapia para o tratamento ou prevenção de condições associadas a sangramento hipocoagulação - Google Patents

terapia para o tratamento ou prevenção de condições associadas a sangramento hipocoagulação

Info

Publication number
BR112016009954A2
BR112016009954A2 BR112016009954A BR112016009954A BR112016009954A2 BR 112016009954 A2 BR112016009954 A2 BR 112016009954A2 BR 112016009954 A BR112016009954 A BR 112016009954A BR 112016009954 A BR112016009954 A BR 112016009954A BR 112016009954 A2 BR112016009954 A2 BR 112016009954A2
Authority
BR
Brazil
Prior art keywords
bleeding
hypocoagulation
fviia
apc
combination
Prior art date
Application number
BR112016009954A
Other languages
English (en)
Inventor
Gale Andrew
Von Drygalski Annette
H Griffin John
Mosnier Laurent
Original Assignee
Univ California
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Scripps Research Inst filed Critical Univ California
Publication of BR112016009954A2 publication Critical patent/BR112016009954A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

o presente pedido se refere de modo geral a métodos para a prevenção ou tratamento de sangramento ou hipocoagulação em um indivíduo em necessidade em necessidade do mesmo, e a composições para uso em tais métodos. os métodos compreendem administração de fva, de preferência um fva resistente a apc (tal como superfva), individualmente ou em combinação com fviia, de preferência rhfviia (tal como novoseven® ou outro fviia com atividade ou meia vida intensificada). quando administrados em combinação, fva e fviia provocam um benefício sinérgico quando usados para tratar ou prevenir sangramento ou hipocoagulação em sujeitos em necessidade dos mesmos, por exemplo, sujeitos com um distúrbio genético, tal como hemofilia, ou um distúrbio hemorrágico adquirido ou outra condição associada a sangramento ou hipocoagulação, tal como acidente vascular cerebral ou choque hemorrágico, traumatismo, cirurgia ou dismenorreia, ou indivíduos que produzem anticorpos inibitórios contra pró-coagulantes, tais como fviii ou fix, ou que aos quais tenha sido administrada uma overdose de uma droga anticoagulante, tal como um inibidor direto de xa ou inibidor direto de trombina ou um novo anticoagulante oral (noac) ou apresentam sangramentos inexplicáveis. além disso, a invenção se refere ao uso de um superfva individualmente ou em combinação com fviia ou outro agente pró-coagulante ou pró-hemostático para prevenir, tratar ou reverter sangramento associado a apc, por exemplo, como resultado da superprodução de apc (tal como através de ferimentos graves e/ou choque hemorrágico) ou terapia com apc ou outro anticoagulante, por exemplo, no tratamento de distúrbios inflamatórios ou sepse.
BR112016009954A 2013-11-04 2014-11-04 terapia para o tratamento ou prevenção de condições associadas a sangramento hipocoagulação BR112016009954A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361899544P 2013-11-04 2013-11-04
US201461944915P 2014-02-26 2014-02-26
PCT/US2014/063898 WO2015066700A2 (en) 2013-11-04 2014-11-04 Therapy for treatment or prevention of conditions associated with bleeding or hypocoagulation

Publications (1)

Publication Number Publication Date
BR112016009954A2 true BR112016009954A2 (pt) 2017-12-05

Family

ID=53005421

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016009954A BR112016009954A2 (pt) 2013-11-04 2014-11-04 terapia para o tratamento ou prevenção de condições associadas a sangramento hipocoagulação

Country Status (8)

Country Link
US (1) US10407488B2 (pt)
EP (1) EP3065768B1 (pt)
JP (1) JP2017500372A (pt)
KR (1) KR20160070163A (pt)
CN (1) CN105848668A (pt)
BR (1) BR112016009954A2 (pt)
CA (1) CA2929671A1 (pt)
WO (1) WO2015066700A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4299585A3 (en) * 2016-05-13 2024-04-17 The Scripps Research Institute Compositions and methods for anti-thrombotic and hemostatic therapies
MX2019002510A (es) * 2016-09-06 2019-06-24 Chugai Pharmaceutical Co Ltd Metodos para usar un anticuerpo biespecifico que reconoce el factor de coagulacion ix y/o el factor de coagulacion ix activado y el factor de coagulacion x y/o factor de coagulacion x activado.
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
CN109316599A (zh) * 2018-08-24 2019-02-12 上海交通大学医学院附属瑞金医院 一种抑肽酶或其突变体、衍生物、类似物或其组成片段的应用
CN109260462B (zh) * 2018-08-24 2021-05-11 上海交通大学医学院附属瑞金医院 一种凝血酶原突变体蛋白及其编码核酸的应用
DK3723858T3 (da) 2018-12-21 2022-01-24 Kymab Ltd Fixaxfx bispecifik antistof med fælles let kæde
BR112021015068A2 (pt) * 2019-02-01 2021-10-05 Takeda Pharmaceutical Company Limited Métodos de tratamento profilático usando vwf recombinante (rvwf)
US11654057B2 (en) 2020-04-09 2023-05-23 Bio 54, Llc Devices for bleeding reduction and methods of making and using the same
CN114364394A (zh) * 2020-05-26 2022-04-15 约翰内斯·古滕伯格美因兹大学医学院 用于治疗冠状病毒感染及相关凝血病的方法和组合物
US11642324B1 (en) 2022-03-01 2023-05-09 Bio 54, Llc Topical tranexamic acid compositions and methods of use thereof
US20240075001A1 (en) * 2022-05-24 2024-03-07 Darren Rubin Methods to reduce hemorrhage and mortality on the battlefield and applications for trauma patients
CN116426510B (zh) * 2023-06-13 2023-09-22 北京沃森赛瑟生物技术有限公司 含修饰Xa因子的利伐沙班检测试剂盒及检测方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831005A (en) 1992-09-24 1998-11-03 Chiron Corporation Synthesis of N-substituted oligomers
US5877278A (en) 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
DE4416166C2 (de) * 1994-05-06 1997-11-20 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen
WO2002103024A2 (en) * 2001-06-14 2002-12-27 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
US7125846B2 (en) 2001-11-09 2006-10-24 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
CN1596125A (zh) * 2001-11-09 2005-03-16 诺和诺德医疗保健公司 包括因子ⅶ多肽和因子ⅴ多肽的药物组合物
EP2081589B1 (en) 2006-11-16 2010-10-06 Crucell Holland B.V. Complementation of factor xi deficiency by factor v mutants
EP2247303A4 (en) 2007-12-20 2011-12-07 Univ Queensland HEMOSTASE MODULATING COMPOSITIONS AND USES THEREFOR
WO2010149172A2 (en) * 2009-06-24 2010-12-29 Rigshospitalet SYSTEMIC PRO-HEMOSTATIC EFFECT OF CLOTTING FACTORS IN COMBINATION WITH SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH.

Also Published As

Publication number Publication date
EP3065768A4 (en) 2017-07-19
CN105848668A (zh) 2016-08-10
CA2929671A1 (en) 2015-05-07
WO2015066700A2 (en) 2015-05-07
JP2017500372A (ja) 2017-01-05
US10407488B2 (en) 2019-09-10
EP3065768A2 (en) 2016-09-14
US20160289299A1 (en) 2016-10-06
EP3065768B1 (en) 2020-09-23
WO2015066700A3 (en) 2015-07-16
KR20160070163A (ko) 2016-06-17

Similar Documents

Publication Publication Date Title
BR112016009954A2 (pt) terapia para o tratamento ou prevenção de condições associadas a sangramento hipocoagulação
MX2016011975A (es) Metodos para reducir el riesgo cardiovascular.
MX2020009246A (es) Uso del inhibidor de pcsk9 para disminuir el riesgo cardiovascular.
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
BR112015006055A2 (pt) composições e métodos para o tratamento e prevenção de lesão tecidual e doença
AR060836A1 (es) Un disco trans-mucosa para administrar un agente activo, una composicion trans-mucosa y el metodo de administracion obtenido
BRPI0511603A (pt) método para o tratamento de distúrbios do sangramento com a utilização de polissacarìdeos sulfatados
BR112013022217A8 (pt) composição farmacêutica, método de tratamento preventivo de uma síndrome hemorrágica em um paciente com hemofilia a ou b e método de tratamento de um acidente hemorrágico em um paciente com hemofilia a ou b
PH12020550821A1 (en) Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
BR112016014008A2 (pt) Piperidinil tetra-hidroquinolinas substituídas e seu uso como antagonistas de adrenoreceptor alfa-2c
ZA202110111B (en) Methods and compositions for treating liver disorders
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
CR20160277A (es) Piperidinil tetrahidroquinolinas sustituidas
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
BR112015014261A8 (pt) composto de danazol, seu uso e formulação farmacêutica compreendendo este
JP2013538863A5 (pt)
Diener Pro:“The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.”
MX343784B (es) Factor ii y fibrinogeno para tratamiento de trastornos hemostaticos.
BR112019002194A2 (pt) uso de adamts13 para tratar, melhorar e/ou prevenir a crise vaso-oclusiva na doença falciforme, lesão pulmonar aguda e/ou síndrome da insuficiência respiratória aguda
BR112015017546A2 (pt) composições hemostáticas, usos das mesmas e kit
MX2017015129A (es) Composicion y usos de la misma.
Martínez-Mejorada et al. Effectiveness of polyhexamethylene biguanide dressings vs. platelet-rich plasma in diabetic foot ulcer: a pilot study of case series
EA201300843A1 (ru) Карбамоилфенильные производные для остановки, предотвращения и профилактики кровотечений или усиления системы гемостаза
Jiménez-Yuste et al. Long-term follow-up of hemophilia a patients who previously showed complete or partial success in immune tolerance induction therapy with a single plasma-derived FVIII/VWF product: Long-term ITI study

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2450 DE 19-12-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.